ATE526019T1 - Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen - Google Patents
Verfahren zur behandlung von zellproliferationen störungen und virusinfektionenInfo
- Publication number
- ATE526019T1 ATE526019T1 AT01972917T AT01972917T ATE526019T1 AT E526019 T1 ATE526019 T1 AT E526019T1 AT 01972917 T AT01972917 T AT 01972917T AT 01972917 T AT01972917 T AT 01972917T AT E526019 T1 ATE526019 T1 AT E526019T1
- Authority
- AT
- Austria
- Prior art keywords
- treating cell
- cell proliferation
- virus infections
- proliferation disorders
- viral infections
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22141500P | 2000-07-28 | 2000-07-28 | |
US24526400P | 2000-11-02 | 2000-11-02 | |
PCT/US2001/023640 WO2002009696A1 (en) | 2000-07-28 | 2001-07-27 | Methods for treating cell proliferative disorders and viral infections |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE526019T1 true ATE526019T1 (de) | 2011-10-15 |
Family
ID=26915764
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT01972917T ATE526019T1 (de) | 2000-07-28 | 2001-07-27 | Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen |
Country Status (8)
Country | Link |
---|---|
US (1) | US6946456B2 (de) |
EP (1) | EP1322307B1 (de) |
JP (1) | JP2004505044A (de) |
KR (1) | KR20030046397A (de) |
AT (1) | ATE526019T1 (de) |
AU (2) | AU9254801A (de) |
CA (1) | CA2417495C (de) |
WO (1) | WO2002009696A1 (de) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7439359B2 (en) * | 2000-11-02 | 2008-10-21 | Sloan-Kettering Institute For Cancer Research | Small molecule compositions for binding to hsp90 |
US20090197852A9 (en) * | 2001-08-06 | 2009-08-06 | Johnson Robert G Jr | Method of treating breast cancer using 17-AAG or 17-AG or a prodrug of either in combination with a HER2 inhibitor |
US6872715B2 (en) | 2001-08-06 | 2005-03-29 | Kosan Biosciences, Inc. | Benzoquinone ansamycins |
EP1440072A4 (de) | 2001-10-30 | 2005-02-02 | Conforma Therapeutic Corp | Purinanaloga mit hsp90-inhibierender wirkung |
WO2003066005A2 (en) | 2002-02-08 | 2003-08-14 | Conforma Therapeutics Corporation | Ansamycins having improved pharmacological and biological properties |
WO2003079936A1 (en) * | 2002-03-18 | 2003-10-02 | Medtronic Ave Inc. | Medical devices for delivering anti-proliferative compositions to anatomical sites at risk for restenosis |
US20060014730A1 (en) * | 2002-04-10 | 2006-01-19 | Conforma Therapeutics Corporation | Ansamycin formulations and methods for producing and using same |
US20060148776A1 (en) * | 2003-03-13 | 2006-07-06 | Conforma Therapeutics Corporation | Drug formulations having long and medium chain triglycerides |
US7691838B2 (en) * | 2003-05-30 | 2010-04-06 | Kosan Biosciences Incorporated | Method for treating diseases using HSP90-inhibiting agents in combination with antimitotics |
CA2539548A1 (en) | 2003-09-18 | 2005-03-31 | Conforma Therapeutics Corporation | Novel heterocyclic compounds as hsp90-inhibitors |
WO2005031002A2 (en) * | 2003-09-22 | 2005-04-07 | Rosetta Inpharmatics Llc | Synthetic lethal screen using rna interference |
EP1716119B1 (de) | 2003-12-23 | 2013-03-06 | Infinity Discovery, Inc. | Analoga von benzochinonhaltigen Ansamycinen zur Behandlung von Krebs |
US20050256097A1 (en) * | 2004-05-11 | 2005-11-17 | Kosan Biosciences, Inc. | Pharmaceutical solution formulations containing 17-AAG |
US20060067953A1 (en) * | 2004-09-29 | 2006-03-30 | Conforma Therapeutics Corporation | Oral pharmaceutical formulations and methods for producing and using same |
DE102004049078A1 (de) | 2004-10-08 | 2006-04-13 | Merck Patent Gmbh | Phenylpyrazole |
CA2586612C (en) * | 2004-11-18 | 2016-10-11 | Synta Pharmaceuticals Corp. | Triazole compounds that modulate hsp90 activity |
US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
HUE038768T2 (hu) * | 2005-02-18 | 2018-11-28 | Abraxis Bioscience Llc | Terápiás szerek kombinációi, valamint beadásukra szolgáló módszerek, és kombinációs terápia |
DE102005009440A1 (de) | 2005-03-02 | 2006-09-07 | Merck Patent Gmbh | Thienopyridinderivate |
JP2008535844A (ja) * | 2005-04-07 | 2008-09-04 | コンフォーマ・セラピューティクス・コーポレイション | リン脂質をベースとする医薬製剤およびその製造および使用方法 |
CN101213178A (zh) | 2005-06-29 | 2008-07-02 | 协和发酵工业株式会社 | 苯环型安莎霉素衍生物 |
EP1928846B1 (de) | 2005-08-18 | 2014-06-04 | Synta Pharmaceuticals Corp. | Hsp90-aktivität modulierende triazolverbindungen |
CN101360492A (zh) * | 2005-12-01 | 2009-02-04 | 康福玛医药公司 | 含安莎霉素的组合物 |
SI1971338T1 (sl) * | 2005-12-22 | 2011-06-30 | Astrazeneca Ab | Kombinacija ZD6474 in pemetrekseda |
US20070167422A1 (en) * | 2006-01-18 | 2007-07-19 | Yu Kwok S | Pharmaceutical compositions comprising 17-allylamino-17-demethoxygeldanamycin |
US20070259820A1 (en) * | 2006-05-03 | 2007-11-08 | The Regents Of The University Of Michigan | Methods and reagents for activating heat shock protein 70 |
CA2653327A1 (en) * | 2006-05-25 | 2007-12-06 | Synta Pharmaceuticals Corp. | Compounds that modulate hsp90 activity and methods for identifying same |
AR061185A1 (es) | 2006-05-26 | 2008-08-13 | Chugai Pharmaceutical Co Ltd | Compuestos heterociclicos como inhibidores de hsp90. composiciones farmaceuticas. |
US8067412B2 (en) * | 2006-08-11 | 2011-11-29 | Universite De Strasbourg | Macrocyclic compounds useful as inhibitors of kinases and HSP90 |
DE102007002715A1 (de) | 2007-01-18 | 2008-07-24 | Merck Patent Gmbh | Triazolderivat |
TW200904435A (en) | 2007-03-01 | 2009-02-01 | Chugai Pharmaceutical Co Ltd | Macrocyclic compounds |
DE102007028521A1 (de) | 2007-06-21 | 2008-12-24 | Merck Patent Gmbh | Indazolamidderivate |
DE102007032739A1 (de) | 2007-07-13 | 2009-01-15 | Merck Patent Gmbh | Chinazolinamidderivate |
DE102007041116A1 (de) | 2007-08-30 | 2009-03-05 | Merck Patent Gmbh | 1,3-Dihydro-isoindolderivate |
US20110190237A1 (en) * | 2008-01-15 | 2011-08-04 | Nexgenix Pharmaceuticals | Macrocyclic Prodrug Compounds Useful as Therapeutics |
AU2009208947B2 (en) | 2008-02-01 | 2014-02-06 | Takeda Pharmaceutical Company Limited | Oxim derivatives as HSP90 inhibitors |
JP2012510444A (ja) * | 2008-11-28 | 2012-05-10 | ノバルティス アーゲー | 治療的処置のためのHsp90阻害剤 |
DE102008061214A1 (de) | 2008-12-09 | 2010-06-10 | Merck Patent Gmbh | Chinazolinamidderivate |
DE102009054302A1 (de) | 2009-11-23 | 2011-05-26 | Merck Patent Gmbh | Chinazolinderivate |
WO2011123393A1 (en) | 2010-03-29 | 2011-10-06 | Abraxis Bioscience, Llc | Methods of enhancing drug delivery and effectiveness of therapeutic agents |
MX364637B (es) | 2010-03-29 | 2019-05-03 | Abraxis Bioscience Llc Star | Platino y nanopartículas que incluyen placlitaxel/albúmina para usarse en el trartamiento de nsclc. |
EP2560640A1 (de) | 2010-04-19 | 2013-02-27 | Synta Pharmaceuticals Corp. | Krebstherapie mit einer kombination aus hsp90-inhibitorverbindungen und einem egfr-hemmer |
MY162903A (en) | 2010-06-04 | 2017-07-31 | Abraxis Bioscience Llc | Methods of treatment of pancreatic cancer |
DE102010046837A1 (de) | 2010-09-29 | 2012-03-29 | Merck Patent Gmbh | Phenylchinazolinderivate |
EP2773345A1 (de) | 2011-11-02 | 2014-09-10 | Synta Pharmaceuticals Corp. | Krebstherapie unter verwendung einer kombination aus hsp90-inhibitoren mit topoisomerase-i-inhibitoren |
US20140286902A1 (en) | 2011-11-02 | 2014-09-25 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitors with platinum-containing agents |
US9402831B2 (en) | 2011-11-14 | 2016-08-02 | Synta Pharmaceutical Corp. | Combination therapy of HSP90 inhibitors with BRAF inhibitors |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3595955A (en) | 1969-03-26 | 1971-07-27 | Upjohn Co | Geldanamycin and process for producing same |
US4261989A (en) | 1979-02-19 | 1981-04-14 | Kaken Chemical Co. Ltd. | Geldanamycin derivatives and antitumor drug |
KR920000763A (ko) * | 1990-06-06 | 1992-01-29 | 가와무라 요시부미 | 라디시콜 유도체, 그 제조방법 및 그의 항종양 활성 |
US5650430A (en) * | 1990-06-06 | 1997-07-22 | Sankyo Company, Limited | Radicicol derivatives, their preparation and their anti-tumor activity |
US5387584A (en) * | 1993-04-07 | 1995-02-07 | Pfizer Inc. | Bicyclic ansamycins |
US5932566A (en) | 1994-06-16 | 1999-08-03 | Pfizer Inc. | Ansamycin derivatives as antioncogene and anticancer agents |
US5731343A (en) * | 1995-02-24 | 1998-03-24 | The Scripps Research Institute | Method of use of radicicol for treatment of immunopathological disorders |
DE69728974T2 (de) * | 1996-10-25 | 2005-03-31 | Kyowa Hakko Kogyo Co., Ltd. | Radicicolderivate |
JP4903922B2 (ja) * | 1997-05-14 | 2012-03-28 | スローン − ケッタリング インスティチュート フォー キャンサー リサーチ | 選択された蛋白質を分解する複合化合物 |
US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
BR0011182A (pt) | 1999-04-02 | 2003-06-10 | Euro Celtique Sa | Derivados de purina tendo atividade inibidora de fosfodiesterase iv |
CA2370007A1 (en) | 1999-04-09 | 2000-10-19 | Sloan-Kettering Institute For Cancer Research | Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases |
US6335157B1 (en) | 1999-05-07 | 2002-01-01 | The European Molecular Biology Laboratory | Method based on localization of Hsp90 to the centrosome |
GB9924020D0 (en) | 1999-10-11 | 1999-12-15 | Pfizer Ltd | Pharmaceutically active compounds |
JP2004504356A (ja) * | 2000-07-20 | 2004-02-12 | メルク エンド カムパニー インコーポレーテッド | C型肝炎ウイルスのプロセシングおよび複製の抑制 |
US7211562B2 (en) * | 2000-11-02 | 2007-05-01 | Sloan-Kettering Institute For Cancer Research | Methods for enhancing the efficacy of cytotoxic agents through the use of HSP90 inhibitors |
-
2001
- 2001-07-27 KR KR10-2003-7001269A patent/KR20030046397A/ko active Search and Examination
- 2001-07-27 CA CA2417495A patent/CA2417495C/en not_active Expired - Lifetime
- 2001-07-27 US US10/343,246 patent/US6946456B2/en not_active Expired - Lifetime
- 2001-07-27 EP EP01972917A patent/EP1322307B1/de not_active Revoked
- 2001-07-27 JP JP2002515249A patent/JP2004505044A/ja active Pending
- 2001-07-27 AU AU9254801A patent/AU9254801A/xx active Pending
- 2001-07-27 AT AT01972917T patent/ATE526019T1/de not_active IP Right Cessation
- 2001-07-27 AU AU2001292548A patent/AU2001292548B2/en not_active Expired
- 2001-07-27 WO PCT/US2001/023640 patent/WO2002009696A1/en active IP Right Grant
Also Published As
Publication number | Publication date |
---|---|
EP1322307A4 (de) | 2008-08-13 |
AU9254801A (en) | 2002-02-13 |
US20030216369A1 (en) | 2003-11-20 |
US6946456B2 (en) | 2005-09-20 |
CA2417495A1 (en) | 2002-02-07 |
EP1322307B1 (de) | 2011-09-28 |
CA2417495C (en) | 2013-04-30 |
AU2001292548B2 (en) | 2005-06-16 |
WO2002009696A1 (en) | 2002-02-07 |
EP1322307A1 (de) | 2003-07-02 |
KR20030046397A (ko) | 2003-06-12 |
JP2004505044A (ja) | 2004-02-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE526019T1 (de) | Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen | |
CY1119263T1 (el) | Συνθεσεις και μεθοδοι για την αυξηση της ασβεστοποιησεως των οστων | |
EP1408986A4 (de) | Proteomimetische verbindungen und verfahren | |
DK1062226T3 (da) | Nukleinsyreligander med høj affinitet mod komplementsystemets C5-protein | |
ATE508635T1 (de) | Virusvektoren und ihre verwendung bei therapeutischen methoden | |
EA199801031A1 (ru) | Ингибиторы протеинфарнезилтрансферазы | |
DE60137631D1 (de) | Ireovirus antikörpern zur behandlung von ras-vermittelten, proliferativen erkrankungen | |
ATE542801T1 (de) | Zur behandlung von neoplastischen krankheiten, entzündlichen erkrankungen und erkrankungen des immunsystems geeignete 2,4-pyrimidindiamine | |
CY1116385T1 (el) | Αντινοηματικη διαμορφωση της εκφρασης της απολιποπρωτεινης β | |
DE69931377D1 (de) | Verfahren zur behandlung von ig-e assozierten krankheiten und zusammensetzungen zur verwendung in diesen verfahren | |
DE60039415D1 (de) | Reovirus zur behandlung von zellulären proliferativen erkrankungen | |
WO2002069900A3 (en) | Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors | |
ATE466080T1 (de) | Formulierungen und verfahren zum denaturieren von proteinen | |
DK1278868T3 (da) | Muteret form af arginindeiminase | |
ATE290315T1 (de) | Von humanem hitzeschockprotein 60 hergeleitete peptide zur behandlung von diabetis, entsprechende zusammensetzungen, verfahren und kits | |
BRPI0412441A (pt) | método para estabilizar um crioprecipitado de proteìnas plasmáticas para ser submetido a um tratamento térmico de inativação viral | |
ATE302002T1 (de) | Verwendung von pyrazolderivaten zur behandlung von unfruchtbarkeit | |
DE69433243D1 (de) | Verwendunf von ApoE zum Binden von TAU und MAP2c Proteinen und zur Behandlung von Alzheimer's Krankheit | |
ATE287722T1 (de) | Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1 | |
ATE313561T1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
ATE225171T1 (de) | Aminosäurederivate zur behandlung von schlaganfall | |
DE69927668D1 (de) | Massenfingerabdrucken und seiner verwendung zur identifizierung von protein-affinitätsliganden | |
DE69733948D1 (de) | In vivo herstellung von replicativen molekülen | |
DE60229924D1 (de) | Fusionsproteine zur spezifisichen behandlung von krebs und autoimmunkrankheiten | |
DE60334289D1 (de) | Dithiolopyrrolon-derivate zur behandlung von proliferativen störungen |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |